The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTILS.L Share News (TILS)

  • There is currently no data for TILS

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK DIRECTOR DEALINGS SUMMARY: IG Design CEO Sells GBP528,000 In Shares

Thu, 10th Dec 2020 15:30

(Alliance News) - The following is a round-up of share dealings by London-listed company directors and managers announced on Thursday and not separately reported by Alliance News:

----------

IG Design Group PLC - Milton Keynes, Bedfordshire-based consumer gift packaging - Chief Executive Officer Paul Fineman sells 87,304 shares via Howard Gary Fineman Intestacy Trust at 605.0 pence, worth GBP528,189, on Thursday. The trust continues to hold 87,304 shares, having sold half its holding.

----------

Tiziana Life Sciences PLC - London-based therapeutics for oncology, inflammation and infectious diseases - Executive Chair Gabriele Cerrone buys 35,000 shares via Panetta Partners Ltd at 78p, worth GBP27,300, on Wednesday. Cerrone's interest remains about 34.1%.

----------

React Group PLC - South Derbyshire-based cleaning, hygiene and decontamination - Non-Executive Director Rob Gilbert buys 740,185 shares at 1.35p, worth GBP9,992, on Wednesday. Now has 6.0 million shares, a 0.2% stake. CEO Shaun Doak buys 150,000 at 1.33p, also on Wednesday. They are his only shares.

----------

Harworth Group PLC - Rotherham, South Yorkshire-based land and property regeneration - Non-Executive Director Patrick Bourke buys 40,000 shares at GBP1.05, worth GBP41,900, on Thursday. Bourke joined the board at the start of November. He is the former finance director of John Laing Group PLC, stepping down in 2019.

----------

Jaywing PLC - Sheffield, England-based data-driven media consultancy - CEO Andrew Fryatt buys 96,969 shares at 6.6p, worth GBP6,400, on Thursday. They are his only shares, having been appointed as CEO in March.

----------

By Tom Waite; thomaslwaite@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
7 Feb 2019 11:40

Tiziana Life Sciences Non-Exec Director Riccardo Dalla-Favera Resigns

LONDON (Alliance News) - Tiziana Life Sciences PLC on Thursday said Non-Executive Director Riccardo Dalla-Favera has resigned from his role."The company is grateful to Favera for his

Read more
3 Dec 2018 14:27

Tiziana completes patient enrolment in ongoing Milciclib study

(Sharecast News) - Biotechnology company Tiziana Life Sciences announced on Monday that patient enrolment in its ongoing Phase 2a clinical trial, known as CDKO-125A-010, was now completed.

Read more
3 Dec 2018 11:51

Tiziana Life Completes Patient Enrollment In Liver Cancer Trial

LONDON (Alliance News) - Tiziana Life Sciences PLC on Monday said it completed patient enrollment in a Phase 2a trial of Milciclib in hepatocellular carcinoma.The company explained that the

Read more
28 Nov 2018 12:19

Tiziana Life Sciences Begins First-In-Human Phase 1 Trial Of Foralumab

LONDON (Alliance News) - Tiziana Life Sciences PLC on Wednesday said it began the first in-human trial of Foralumab, a treatment for autoimmune diseases.The biotechnology company said the a

Read more
20 Nov 2018 12:53

Tiziana Life Sciences Prices ADS Offering, Raises GBP3.4 Million

LONDON (Alliance News) - Tiziana Life Sciences PLC said Tuesday that it has priced its underwritten public offering in the US of 442,910 American Depositary Shares representing ordinary shares in

Read more
25 Sep 2018 13:43

Tiziana Life Seeks Listing Of ADS On Nasdaq Capital Market (ALLIPO)

LONDON (Alliance News) - Tiziana Life Sciences PLC said Tuesday that it has commenced underwritten public offering in the US of American Depositary Shares representing ordinary shares in the UK of

Read more
24 Sep 2018 12:37

Tiziana Half-Year Loss Unchanged; Gets US Approval For Foralumab Trial

LONDON (Alliance News) - Tiziana Life Sciences PLC on Monday reported a flat loss in the first half of 2018 as expenses were broadly unchanged, while the biotechnology firm also announced that its

Read more
17 Aug 2018 11:39

DIRECTOR DEALINGS: Tiziana Life Chairman Associate Buys Shares

LONDON (Alliance News) - Tiziana Life Sciences PLC said Friday that Panetta Partners Ltd, a company associated with Chairman Gabriele Cerrone, bought shares in the company worth acquired 469,766 a

Read more
16 Aug 2018 11:47

Tiziana seeks trial for multiple sclerosis 'game changer'

(Sharecast News) - Tiziana Life Sciences on Thursday submitted an application to initiate phase one clinical trials for a new treatment of neurodegenerative diseases to the US food and drug administration.

Read more
27 Jul 2018 11:14

Tiziana Life Sciences Files For IPO Of American Depositary Shares (ALLIPO)

LONDON (Alliance News) - Tiziana Life Sciences PLC said Friday it filed a registration statement with the US Securities Exchange Commission for a proposed initial public offering of its American

Read more
16 May 2018 13:27

Tiziana Life Science Reports Progress In Milcicib Phase 2a Trial

LONDON (Alliance News) - Biotechnology company Tiziana Life Sciences PLC said Wednesday that the phase 2a trial of Milciclib safety and tolerability in patients with Metastatic Hepatocellular has

Read more
19 Apr 2018 14:44

Tiziana Raises GBP825,000 Through Placing Of 1 Million Shares (ALLISS)

LONDON (Alliance News) - Tiziana Life Sciences PLC said Thursday it has raised GBP825,000 from the issue of 1.0 million new shares at a price of 80 pence per share.The cancer and autoimmune

Read more
4 Apr 2018 12:53

Tiziana Appoints Leopoldo Zambeletti As Non-Executive Director

LONDON (Alliance News) - Tiziana Life Sciences PLC, a biotechnology company developing drugs for cancer and autoimmune diseases, said Wednesday Leopoldo Zambeletti has joined

Read more
16 Nov 2016 09:34

Tiziana Life Sciences makes breakthrough oral treatment for inflammatory diseases

(ShareCast News) - Tiziana Life Sciences, the clinical stage biotechnology company, announced that new data has demonstrated the potential of its novel oral therapy with foralumab for non-alcoholic steatohepatitis (NASH), diabetes and other life threatening inflammatory diseases. Oral efficacy in hu

Read more
18 Jul 2016 12:03

Tiziana Life looks for secrets of long life with new acquisition

(ShareCast News) - Tiziana Life Sciences has purchased key assets from Sardinia-based biobanking and genomics research company Shardna for €258,000, giving it access to the genetic data of nearly 13,000 people from the Ogliastra region, where life expectancy is high. The AIM-listed clinical stage bi

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.